This press release contains forward-looking statements about Amylin, Lilly and Alkermes. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that exenatide and the revenues generated from exenatide may be affected by competition; unexpected new data; technical issues; clinical trials not confirming previous results; pre-clinical trials not predicting future results; new drug applications and label expansion requests, not being submitted in a timely manner or receiving regulatory approval; or manufacturing and supply issues. The potential for exenatide may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in the companies' most recently filed United States Securities and Exchange Commission documents including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. The companies undertake no duty to update these forward-looking statements.
P--LLY
(i) The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-8.... Accessed on June 5, 2009.
(ii) The International Diabetes Federation Diabetes Atlas. Available at: http://www.eatlas.idf.org/index29fc.html.... June 5, 2009.
(iii) Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281 (21):2005-2012.
(iv) The International Diabetes Federation Diabetes Atlas. Available at http://www.eatlas.idf.org/index755a.html.... Accessed on June 5, 2009.
(v) The International Diabetes Federation Diabetes Atlas. Available at http://www.eatlas.idf.org/index711b.html.... Accessed on June 5, 2009.
(vi) The International Diabetes Federation, Diabetes Atlas, 2003 Second edition. Available at: http://www.idf.org/webdata/docs/backgrou.... Accessed June 5, 7 Jun. (vii) - Kolterman, O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T, Taylor K, Kim D, Aisporna M, Wang Y, Baron A. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2003; 88(7):3082-3089.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20071031/CLW032LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO )
Amylin: Anne Erickson, +1-858-754-4443, Cell: +1-858-349-3195, anne.erickson@amylin.com; or Lilly: Tim Coulom, +1-317-655-2998, Cell: +1-317-554-9757, coulomtd@lilly.com; or Alkermes: Rebecca Peterson, +1-617-583-6378, Cell: +1-617-899-2447, rebecca.peterson@alkermes.com; Photo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, http://www.newscom.com/cgi-bin/prnh/20071031/CLW032LOGO, http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO
